Durham NC 三阴性乳腺癌临床试验
12项针对 三阴性乳腺癌的研究正在 Durham及周边约 30 英里内的站点招募参与者。打开研究详情可查看入选标准及联系研究团队的方式。
官方研究文本（英文）
正在为研究招募参与者？将此页面置顶展示 — $99 / 30天 →
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
招募中1/2 期
- Duke University, Durham
Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies
招募中2 期
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill · 距离 10 英里
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
招募中3 期
- Duke Cancer Institute, Durham
- Lineberger Comprehensive Cancer Center, Chapel Hill · 距离 10 英里
Toci +/- SOC Chemo for Metastatic Triple Negative and ER-positive, HER2-negative Breast Cancers
招募中2 期
- Duke University, Durham
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
招募中2/3 期
- Duke Cancer Institute, Durham
DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs
招募中2 期
- Duke University Medical Center, Durham
Study of Autologous CAR-T Cells Targeting B7-H3 in TNBC iC9-CAR.B7-H3 T Cells
招募中1 期
- University of North Carolina, Chapel Hill · 距离 10 英里
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
招募中1 期
- Duke Cancer Institute /ID# 276267, Durham
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
招募中2 期
- The University of North Carolina at Chapel Hill, Chapel Hill · 距离 10 英里
Preoperative Chemotherapy, Pembrolizumab and Low or High Dose RADiation in an Expansion Cohort of Node(+), Triple Negative Breast Cancer
招募中2 期
- University of North Carolina, Chapel Hill · 距离 10 英里
PREDICT-RD: ctDNA Surveillance in TNBC With Residual Disease
招募中2 期
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · 距离 10 英里
A Study of NX-1607 in Adults With Advanced Malignancies
招募中1 期
- University of North Carolina, Chapel Hill · 距离 10 英里
其他城市的 三阴性乳腺癌试验
- Houston, TX42 项研究
- New York City, NY31 项研究
- Nashville, TN28 项研究
- Los Angeles, CA27 项研究
- Boston, MA26 项研究
- San Antonio, TX23 项研究
- St. Louis, MO21 项研究
- Arlington, VA20 项研究
- Atlanta, GA20 项研究
- Dallas, TX18 项研究
- Chicago, IL16 项研究
- Columbus, OH16 项研究
Durham的其他研究
- 乳腺癌64 项研究
- 癌症（所有类型）58 项研究
- 非小细胞肺癌39 项研究
- 多发性骨髓瘤37 项研究
- 急性髓系白血病33 项研究
- 转移性癌症33 项研究
- 前列腺癌32 项研究
- 肺癌32 项研究
- 结直肠癌28 项研究
- 卵巢癌27 项研究
- 慢性淋巴细胞白血病27 项研究
- 心力衰竭26 项研究
数据来自 ClinicalTrials.gov，检索日期：2026年10月6日。每项研究自行设定入选标准，由研究团队决定谁能参与。